An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis-Reference-Cited by-同舟云学术

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis

Published:2022-09 Issue:10 Volume:11 Page:1294-1304
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Valenzuela Belén¹,Olsson Gisleskog Per²,Poggesi Italo³,Sidorenko Tatiana⁴,Burcklen Michel⁴,Kracker Hilke⁴,Pérez‐Ruixo Juan Jose¹

Affiliation:

1. Janssen‐Cilag Spain Part of Janssen Pharmaceutical Companies Madrid Spain

2. POG Pharmacometrics London UK

3. Janssen‐Cilag Italy Part of Janssen Pharmaceutical Companies Cologno Monzese Italy

4. Actelion Pharmaceuticals Ltd Part of Janssen Pharmaceutical Companies Allschwil Switzerland

Funder

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12778

Reference23 articles.

1. Multiple sclerosis

2. Multiple sclerosis – a review

3. Relapses and Progression of Disability in Multiple Sclerosis

4. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

5. Atlas of MS 3rd Edition.https://www.msif.org/wp‐content/uploads/2020/10/Atlas‐3rd‐Edition‐Epidemiology‐report‐EN‐updated‐30‐9‐20.pdf. Accessed March 2021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review;Multiple Sclerosis Journal;2024-06-07

2. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis;Clinical Pharmacokinetics;2023-09-30

3. Pharmacokinetic‐Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis;Clinical Pharmacology & Therapeutics;2023-01-30